secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001140361-23-046804
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q1 FY2024 revenue $78.7M, pro-forma +5.7%; adj. loss $(0.12)/share
--------------------------------------------------------------------------------

- Net sales $78.7M (ex-Dialysis/BioSentry +5.7% YoY); Med Tech +13.3% on Auryon +25.7%, NanoKnife +34.5%.
- GAAP net income $45.9M ($1.15 EPS) includes $47.8M gain from Dialysis/BioSentry sale; adjusted loss $(0.12)/share.
- Completed sale of Dialysis & BioSentry to Merit Medical for $100M cash; proceeds used to extinguish debt.
- Reaffirmed FY2024 outlook: net sales $328-333M, gross margin ~50-52%, adjusted EPS loss $(0.28)-(0.34).
- Cash & equivalents $57.6M at Aug 31, 2023, up from $44.6M at May 31, 2023; debt-free post-divestiture.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036123046804/0001140361-23-046804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036123046804/ef20011918_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-046804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer